Nitric oxide synthesis in the basolateral complex of the amygdala is required for the consolidation and expression of fear potentiated startle but not shock sensitization of the acoustic startle

Targeting neuronal nitric oxide synthase and the nitrergic system in post-traumatic stress disorder

RATIONALE

Current pharmacological approaches to treatment of post-traumatic stress disorder (PTSD) lack adequate effectiveness. As a result, identifying new molecular targets for drug development is necessary. Furthermore, fear learning and memory in PTSD can undergo different phases, such as fear acquisition, consolidation, and extinction. Each phase may involve different cellular pathways and brain regions. As a result, effective management of PTSD requires mindfulness of the timing of drug administration. One of the molecular targets currently under intense investigation is the N-methyl-D-aspartate (NMDA)-type glutamate receptor (NMDAR). However, despite the therapeutic efficacy of drugs targeting NMDAR, their translation into clinical use has been challenging due to their various side effects. One possible solution to this problem is to target signaling proteins downstream to NMDAR to improve targeting specificity. One of these proteins is the neuronal nitric oxide synthase (nNOS), which is activated following calcium influx through the NMDAR.

OBJECTIVE

In this paper, we review the literature on the pharmacological modulation of nNOS in animal models of PTSD to evaluate its therapeutic potential. Furthermore, we attempt to decipher the inconsistencies observed between the findings of these studies based on the specific phase of fear learning which they had targeted.

RESULTS

Inhibition of nNOS may inhibit fear acquisition and recall, while not having a significant effect on fear consolidation and extinction. However, it may improve extinction consolidation or reconsolidation blockade.

CONCLUSIONS

Modulation of nNOS has therapeutic potential against PTSD and warrants further development for use in the clinical setting.

Involvement of nitric oxide in the neurobiology of fear-like behavior

Fear is an emotional reaction that arises in dangerous situations, inducing the adaptation to an existing condition. This behavior was conserved in all vertebrates throughout evolution and is observed in mammals, birds, fish, amphibians, and reptiles. The neurocircuitry of fear involves areas of the limbic system, cortical regions, midbrain, and brainstem. These areas communicate with each other so that there is an expression of fear and memory formation to deal with the same situation at another time. The effect of nitric oxide (NO) on fear modulation has been explored. NO is a gaseous compound that easily diffuses through the cell membrane and is produced through the oxidation reaction of l-Arginine to l-citrulline catalyzed by nitric oxide synthase (NOS). Activating the intracellular NO receptor (soluble guanylyl cyclase enzyme - sGC) triggers an enzymatic cascade that can culminate in plastic events in the neuron. NOS inhibitors induce anxiolytic-like responses in fear modulation, whereas NO donors promote fear- and anxiety-like behaviors. This review describes the neurobiology of fear in mammals and non-mammals, how NO is produced in the central nervous system, and how NO acts in fear-like behavior.

The role of nitric oxide in spatial memory stages, hippocampal ERK and CaMKII phosphorylation

Nitric oxide (NO) is an important intercellular messenger in the control of physiologic functions. It is synthesized by 3 different nitric oxide synthase enzymes (NOS). Uses of non-selective NOS inhibitor (L-NAME) have shown that NO is involved in neuronal plasticity and memory. This study aimed to determine the differential role of NO in spatial memory formation steps. In addition, regarding the roles of ERK and CaMKII in hippocampal plasticity, the hippocampal ERK and CaMKII activities were assessed to identify the effect of L-NAME on those proteins during each phase of memory. Adult male Sprague-Dawely rats weighing 220-280 g were trained in a single session consisting of 8 trials. To evaluate the effect of L-NAME on acquisition, L-NAME (3 or 10 mg/kg/i.p.) was administered 30 min before training. To assess its effect on the consolidation phase, L-NAME (3 or 10 mg/kg/i.p.) was injected immediately after training and a probe test was carried out 24 h later to analyse memory retention. To determine its effect on memory retrieval L-NAME (3 or 10 mg/kg/i.p.) was injected 30 min before probe trial which was conducted 24 h after training. The hippocampi were isolated after behavioural studies and western blotting analysis on hippocampal lysates was performed to illustrate the levels of phosphorylated ERK and CaMKII. The results showed that pre-training administration of L-NAME in 10 mg/kg but not 3mg/kg deteriorates acquisition. Post-training and pre-probe administration of L-NAME in 10 mg/kg but not 3 mg/kg impaired animal's performance in probe test. Additionally L-NAME treatment decreased the amount of phosphorylated (activated) ERK and CaMKII in the hippocampus. This study showed that endogenous nitric oxide is involved not only in all stages of memory, but also in ERK and CaMKII activation in the hippocampus during all 3 stages of memory.